Royalty Report: Drugs, Cancer, Antibody – Collection: 329688

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 13

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 13

Primary Industries

  • Drugs
  • Cancer
  • Antibody
  • Therapeutic
  • Pharmaceuticals
  • Drug Discovery
  • Kidneys
  • Disease
  • Biotechnology

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 329688

License Grant
Licensor, a non-profit teaching hospital, grants an exclusive license under Licensors rights in the Patent Rights to make, have made, use, have used, Sell, have Sold, import and have imported Patented Products and Patented Uses.   Licensor grants the right to  grant sublicenses.
License Property
The Patent application is entitled ALK-Fc exhibits activity in Renal cancer murine xenografts as a single agent and in combination with VEGFR inhibition.

mTOR-targeted inhibitor means a direct inhibitor of the protein called the mammalian target of rapamycin. Each of the following compounds is a non-limiting example of an mTOR-targeted inhibitor everolimus and temsirolimus.

ALKl Product means (i) anALKl (activin receptor-like kinase 1) polypeptide comprising a ligand binding portion of the extracellular domain of a vertebrate ALK 1, particularly human ALKl (e.g. a fusion protein including the ALKl ligand binding domain fused to an Fe p01iion of an IgG); (ii) an antibody that binds to the extracellular domain of human ALKl; (iii) an antibody that binds to human BMP9; or (iv) an antibody that binds to human BMPI0. For clarity, proteins that include the amino acid sequence described as SEQ ID NO 3 or SEQ ID NO5 in U.S. Patent No. 8,158,584 are included in the term ALKl Product.

RTKI means a small-molecule receptor tyrosine kinase inhibitor that binds to and inhibits signaling of VEGFRI, VEGFR2, or VEGFR3. An RTKI may, but need not, bind to and inhibit receptor tyrosine kinases in addition to a VEGFR, such as PDGFRa, PDGFRb, RET and c-Met. Likewise, an RTKI may, but need not, inhibit a different class of kinases that are not cell surface receptors, such as the serine kinases B-raf and c-raf kinase. Each of the following compounds is a non-limiting example of an RTKI sorafenib, pazopanib, axitinib, tivozanib, sunitinib, vandetanib, motesanib, vatalanib and samaxanib.

Field of Use
The Patented Use means the use of an ALKI Product and (i) an RTKI or (ii) an mTORtargeted inhibitor, for the treatment of patients with renal cell carcinoma. Patented Use shall include without limitation the sequential, overlapping or simultaneous dosing of patients with an ALKI Product and the RTKI or mTOR-targeted inhibitor. Patented Use shall also include any additional uses of ALKI Products that are the subject of a valid Claim of the Licensed Patents.

IPSCIO Record ID: 329687

License Grant
The Swiss Licensor, an international non-profit cancer research organization, grants to Licensee an exclusive license under the Licensed Patent Rights to research, develop, make, have made, import have imported. use. have used, sell, have sold, offer for sale, have offered for sale and otherwise exploit Licensed Products in the Field throughout the world.
License Property
Licensed Product means any products the making, selling, using or importing of which is covered by a Valid Claim of a Licensed Patent Right and is (i) an ALK-1 Receptor Product; (ii) an ALK-1 Antibody Product; (iii) an ALK-2 Receptor Product; (iv) an ALK-3 Receptor Product; (v) an ALK-3 Antibody Product; (vi) an ALK4 Receptor Product; (vii) an ALK-4 Antibody Product (viii) an ALK-5 Receptor Product (ix) an ALK-5 Antibody Product; (x) an ALK-6 Receptor Product; (xi) an ALK-6 Antibody Product.

ALK-1 Receptor Product means any product which is comprised at least in part of an extracellular domain of an ALK-1 receptor, as exemplified by amino acids 1-118 of the human ALK-1 sequence presented in U.S. Patent No. 6,316217, or an active po11ion thereof.

ALK-1 Antibody Product means any product which is comprised at least in part of an antibody or a domain of an antibody that binds to an ALK-1 receptor.

ALK-2 Receptor Product means any product which is comprised at least in part of an extracellular domain of an ALK-2 receptor, as exemplified by amino acids 1-124 of the human ALK-2 sequence presented in C .S. Patent No. 6,316,217 or an active portion thereof.

ALK-3 Receptor Product means any product which is comprised at least in part of an extracellular domain of an ALK-3 receptor, as exemplified by amino acids 1-152 of the human ALK-3 sequence presented in U.S. Patent  6.316,217, or an active portion thereof.

ALK-3 Antibody Product means any product which is comprised at least in part of an antibody or a domain of an antibody that binds to an ALK-3 receptor.

ALK-4 Receptor Product means any product which is comprised at least in part of an extracellular domain of an ALK-4 receptor, as exemplified by amino acids 1-126 of the human ALK-4 sequence presented in U.S. Patent No. 6,316,217, or an active portion thereof.

ALK-4 Antibody Product means any product which is comprised at least in part of an antibody or a domain of an antibody that binds to an ALK-4 receptor.

ALK-5 Receptor Product means any product which is comprised at least in part of an extracellular domain of an ALK-5 receptor, as exemplified by amino acids 1-121 of the human ALK-5 sequence presented in U.S. Patent No. 6,316.217, or an active portion thereof.

ALK-5 Antibody Product means any product which is comprised at least in part of an antibody or a domain of an antibody that binds to an ALK-5 receptor.

ALK-6 Receptor Product means any product which is comprised at!east in part of an extracellular domain of an ALK-6 receptor, as exemplified by amino acids 1-122 of the murine ALK-6 sequence presented in U.S. Patent No. 6,316,217, or an active portion thereof.

ALK-6 Antibody Product means any product which is comprised at least in part of an antibody or a domain of an antibody that binds to an ALK-6 receptor.

Field of Use
The patent rights relate to the first cloning of the type I activin receptors, as well as the treatment of pancreatic tumors with dalantercept.

IPSCIO Record ID: 294648

License Grant
For the Development and Commercialization License, the Licensor of the United States and Isreal  grants to the German Licensee an exclusive, world-wide license with the right to sublicense, under the Licensor Existing IP and the Joint Program IP, to develop, manufacture and/or have manufactured and commercialize import, market, sell and otherwise commercialize Licensor Products.

For the Research License, Licensor grants a non-exclusive, world-wide license, without the right to sublicense, under the Licensor Existing IP and the Joint Program IP, to perform the Joint Research Program and the Joint Development Program.

License Property
Licensor Existing IP means the present and future Patent Rights and Know-How owned by Licensor and directed to the 801 polypeptide, to nucleic acid encoding the 801 polypeptide, antibody to the 801 polypeptide, antisense and siRNA to 801 gene and methods of treatment of diseases using these,including but not limited to rights to patents and patent applications.

Licensor Products means Products and Drug Products for the treatment of human diseases other than cancer.

Field of Use
The field of use is for the treatment of human diseases other than cancer.

IPSCIO Record ID: 307845

License Grant
Licensee licensed rights to tivozanib. Pursuant to the license agreement, Licensee obtained an exclusive, sublicensable license to develop, manufacture and commercialize tivozanib worldwide except for Asia and the Middle East, where Licensor retained the rights to tivozanib.
License Property
Tivozanib (FOTIVDA├é┬«) is a vascular endothelial growth factor receptor, or VEGFR, tyrosine kinase inhibitor.  Tivozanib, a potent, selective and long half-life inhibitor of all three vascular endothelial growth factor, or VEGF, receptors is designed to optimize VEGF blockade while minimizing off-target toxicities, resulting in demonstrated improved anti-tumor activity, as measured by progression-free survival, or PFS, overall response rate, or ORR, and duration of response, and tolerability, as measured by the need for significantly fewer dose reductions and interruptions due to adverse events, compared to a non-selective VEGFR TKI, sorafenib.

Licensor is a specialty pharmaceutical company engaged in the development and commercialization of prescription medicines for the treatment of unmet therapeutic needs in major western markets.

Field of Use
The field of use is for the treatment of adult patients with advanced renal cell carcinoma (RCC).  

Renal cell carcinoma (RCC) is a kidney cancer that originates in the lining of the proximal convoluted tubule, a part of the very small tubes in the kidney that transport primary urine.

Licensee is a biopharmaceutical company developing and seeking to commercialize the pipeline of product candidates designed to provide a better life for patients with cancer.  Licensee is working to develop and commercialize tivozanib in North America as a treatment for RCC and hepatocellular carcinoma, or HCC, and is studying tivozanib in combination with immune checkpoint inhibitors for the treatment of RCC and HCC in phase 2 trials.

IPSCIO Record ID: 3200

License Grant
The Licensee exclusively licensed certain patents related to EphA3 from the Licensor, that formed the basis for the KB004 program.
License Property
This gene belongs to the ephrin receptor subfamily of the protein-tyrosine kinase family. EPH and EPH-related receptors have been implicated in mediating developmental events, particularly in the nervous system. Receptors in the EPH subfamily typically have a single kinase domain and an extracellular region containing a Cys-rich domain and 2 fibronectin type III repeats. The ephrin receptors are divided into 2 groups based on the similarity of their extracellular domain sequences and their affinities for binding ephrin-A and ephrin-B ligands. This gene encodes a protein that binds ephrin-A ligands. Two alternatively spliced transcript variants have been described for this gene.  

Anti-EphA3 has shown encouraging preclinical proof-of-concept results in multiple tumor models. The xenograft studies we conducted show that the anti-EphA3 antibody causes growth inhibition in EphA3-positive tumors, as well as in tumors that do not express EphA3 (the latter presumably through the effect on tumor vasculature).

Cancer cells are killed by KB004 binding to EphA3 through apoptosis, or ADCC, at relatively low concentrations. KB004 ex vivo selectively targets and kills leukemic stem cells, but not normal hematopoietic stem cells. In ex vivo assays of these cells, KB004 appears to kill
all cells expressing EphA3.

Field of Use
Under the agreement, the Licensee has rights to develop human antibodies that bind to or modulate EphA3.

IPSCIO Record ID: 256278

License Grant
On the Effective Date the Parties have terminated a certain Collaboration Agreement, and with this agreement, the Parties desire to reallocate the rights and responsibilities of the Parties with respect to further research and development of the GM-CSF Target.

Licensor grants to Licensee of Germany an exclusive, worldwide, license under the Licensor Licensed Technology to Exploit Licensed Products.

Licensor grants a worldwide, non-exclusive, perpetual, irrevocable and non-terminable license under the Collaboration Patents, as defined in the Collaboration Agreement, with the right to grant and authorize the grant of sublicenses, to Exploit Licensed Products.

License Property
BiTE Product means any composition or formulation consisting of or comprising a bi-specific Single Chain Antibody expressed as a single polypeptide chain, binding to T-cells.

GM-CSF Target means the whole or part of the human granulocyte macrophage-colony stimulating factor identified by the SWISS-PROT entry name CSF2 HUMAN and accession number P0414 l.

Single-Chain Antibodies
Antibodies are proteins produced by the body's immune system in response to the presence of antigens, such as bacteria, viruses or other disease causing agents. Antibodies of identical molecular structure that bind to a specific target are called monoclonal antibodies. Single-chain antibodies are genetically engineered antibodies that incorporate only the antigen binding domains of an antibody. Thus, SCAs have the binding specificity and affinity of monoclonal antibodies; however, in their native form they are only one-fifth to one-sixth the size of a monoclonal. The small size of SCAs typically gives them shorter half-lives than monoclonal antibodies, making them better suited for use in acute indications or in other indications where the large size of a monoclonal antibody would inhibit the compound from reaching the area of potential therapeutic activity. In addition, SCAs are a well-established discovery format-of-choice in generating antibodies from phage or yeast display libraries.

Field of Use
The field for Patent 5,223,409 is solely in the field of manufacture, use or sale of Single Chain Antibodies.

The field of use for this agreement otherwise is limited to not include the right to exploit the Products for Radioimmunoguided Surgery(TM), Reagents and kits in the research market for production and cloning of genes encoding Single Chain Antibodies and their fusions in a filamentous bacteriophage-derived vector system, and for expression and screening of Single Chain Antibodies fused with the minor coat protein or attachment or adsorption protein of filamentous bacteriophage, and, Single Chain Antibodies fused with, or for the assay or purification of, Tumor Necrosis l Factor alpha (TNF-a.) or Lymphotoxin.

Products for Radioimmunoguided SurgeryTM (RIGS'), in which a radiolabelled Single Chain Antibody is administered to a cancer patient; time elapses for preferential concentration of the radiolabelled Single Chain Antibody in neoplastic tissue and decrease of background radioactivity in the patient; and such preferentially concentrated radiolabelled Single Chain Antibody is detected within a surgical operative field by a detector probe placed in juxtaposition with tissue suspected of containing said radiolabelled Single Chain Antibody.

IPSCIO Record ID: 280819

License Grant
For the Research the German Licensor grants a non-exclusive research license under Licensor Background Inventions and Licensors rights in Collaboration Data, Collaboration Materials and Collaboration Inventions, to perform its obligations under the Collaboration Plan.

For the Commercial License,  Licensor grants an exclusive, worldwide license to make, have made, use, have used, sell, have sold, offer for sale, import and have imported Licensed Products for use in the Field directed to such Licensee Target under Licensor Background Inventions, and under Licensors rights in all Patent Rights and Collaboration Inventions and Collaboration Material pertaining to such Licensee Target and Licensed Products, or the uses thereof in the Field.

License Property
Licensors HuCAL Technologies shall mean the HuCAL library and associated technologies.   The library data is for a Design of Human Combinatorial Antibody Library-Fab (HuCAL-Fab).
Field of Use
The field shall mean all therapeutic indications.  With this agreement, the Parties will collaborate in the discovery and development of human monoclonal antibodies against certain specified Licensee Targets,  to generate and characterize antibodies and optimize those antibodies and  use their expertise in developing antibodies in pre-clinical and clinical settings.

The two companies will collaborate on the development of human antibodies for the treatment of cancer.

IPSCIO Record ID: 256279

License Grant
The German Licensor grants an exclusive. even as to Licensor, right and license under the Licensed Technology, to make, have made, use, offer for sale, sell, and import Collaboration Products in the Territory for any use in humans.

Licensor grants a worldwide, co-exclusive, with Licensor, right and license, with the right to grant sublicenses, under the Licensor Collaboration Technology to make, have made, use, offer for sale, sell, and import any product that is not a BiTE Product for any use in humans.

License Property
Collaboration Product means any composition or formulation containing a BiTE Molecule binding to a Collaboration Target.

BiTE Molecule means a polypeptide comprising a bi-specific Single Chain Antibody binding to T-cells.

Target means a cell-surface antigen.  The list of proprietary targets is epha2, alpha – V, and, beta-3.

BiTE(R) molecules are part of a novel class of antibody derivatives that may have the potential to selectively direct and activate the human immune system to act against cancer cells. This action is believed to occur as a result of the molecule's stimulation of T cells to target and destroy cancer cells that express a specific antigen.

Field of Use
This product collaboration is useful for the development of antibody-based pharmaceutical products.

BiTE molecule targeting CD19 is for the potential treatment of certain lymphomas.

IPSCIO Record ID: 284140

License Grant
Licensor granted Licensee worldwide exclusive development and commercialization rights to capmatinib and certain back-up compounds in all indications.
License Property
Capmatinib is a potent and highly selective MET inhibitor. The investigational compound has demonstrated inhibitory activity in cell-based biochemical and functional assays that measure MET signaling and MET dependent cell proliferation, survival and migration.
c-Met inhibitors are a class of small molecules that inhibit the enzymatic activity of the c-Met tyrosine kinase, the receptor of hepatocyte growth factor/scatter factor (HGF/SF). These inhibitors may have therapeutic application in the treatment of various types of cancers.
Field of Use
Capmatinib is being evaluated in patients with hepatocellular carcinoma, non-small cell lung cancer and other solid tumors, and may have potential utility as a combination agent.

IPSCIO Record ID: 33130

License Grant
The Licensor of Hong Kong and Licensee of China agree to collaborate with respect to the Development of the Product in the Field with the goal of obtaining Regulatory Approval for Products in the Field in the Territory for Manufacturing and Commercialization. Lilly will have exclusive rights to Commercialize the Products in the Field in the Territory.

For the Exclusive License and Right to Sublicense, Licensor grants an exclusive license, including the right to grant sublicenses, under Licensor Patents, Know-How and Regulatory Approvals to Develop, use, import and Commercialize, but, for clarity, not to make or have made Products in the Field in the Territory.

License Property
Licensor is the owner of a molecule HMPL-013 and is developing it for the Chinese market as a pharmaceutical product useful in the treatment of cancer.

Product means any form or dosage of the HMPL-013 molecule or any analogues or derivatives of the HMPL-013 molecule that are claimed by those Licensor Patents that also claim HMPL-013, in each case that exist as of the Effective Date or are discovered or developed by Licensor during the Term of this Agreement.

HMPL-013, named  Fruquintinib, patents and patent applications report compounds related to Fruquintinib and compositions comprising at least one compound, and methods for inhibiting KDR activity and treating angiogenesis–related disorders with such compounds/compositions.
Fruquintinib is a selective inhibitor of the Vascular Endothelial Growth Factor (VEGF) receptor tyrosine kinases.

Combination Products means any combination or Product and one or more additional active pharmaceutical ingredients, for example in a single delivery device such as a pre-filled pen, dual chamber needle or in a fixed dose combination.

Fruquintinib is a highly selective and potent oral inhibitor of the vascular endothelial growth factor receptor, or VEGFR, and consequently we believe it has the potential to be a global best-in-class VEGFR inhibitor for many types of solid tumors. Based on pre-clinical and clinical data to date, fruquintinibs kinase selectivity has been shown to reduce off-target toxicity. This allows for drug exposure that is able to fully inhibit VEGFR, a protein ligand which contributes to the growth of tumors, and use in potential combinations with other targeted therapies and chemotherapy in earlier lines of treatment with larger patient populations.

Field of Use
Fruquintinib (HMPL-013), is a targeted oncology therapy for the potential treatment of various types of solid tumors.

The Field means all uses.  Initial Indications mean 3rd line colorectal cancer, 3rd line non-small cell lung cancer and 2nd line advanced gastric cancer. Each of the Initial Indications shall be an Initial Indication.

IPSCIO Record ID: 7426

License Grant
This in-License of RXDX-101 and RXDX-102 from the Licensor, an Italian state-owned biopharmaceutical company, grants the Licensee exclusive global rights to develop and commercialize RXDX-101 and RXDX-102.

The development rights under the License Agreement are exclusive for the term of the Agreement with respect to RXDX-101 and RXDX-102 and also, as to the Licensor, are exclusive for a five-year period with respect to any product candidate with activity against the target proteins of RXDX-101 and RXDX-102, and include the right to grant subLicenses.

License Property
RXDX-101 is a tyrosine kinase inhibitor directed to the TrkA, ROS1 and ALK proteins, which is in a Phase I/II clinical study in molecularly defined patient populations for the treatment of solid tumors.

RXDX-102 is a tyrosine kinase inhibitor directed to the Trk family tyrosine kinase receptors, TrkA, TrkB and TrkC, which is currently in preclinical development for the treatment of multiple cancers. Tyrosine kinases are enzymes that transfer phosphate groups from adenosine triphosphate (ATP) to cellular proteins and can function as an on/off switch for cellular functions, including cancer signaling.

IPSCIO Record ID: 371771

License Grant
Licensor of Switzerland hereby grants to Licensee of Denmark (a) an exclusive, royalty-bearing, sublicensable assignable license under the Licensed Data and Product-Specific Patents and (b) a non-exclusive, royalty-bearing, sublicensable assignable license under the Platform Patents, in the case of (a) and (b) solely to Develop and otherwise Commercialize the Licensed Product in the Field in the Territory and to Manufacture and have Manufactured the Compound for use in a Licensed Product in the Field in the Territory as of the Effective Date.
License Property
Licensor own or control the certain Intellectual Property Rights (as defined below) Covering the Compound (as defined below) and has conducted Phase II Clinical Trials and Phase III Clinical Trials of the Compound for the treatment of gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), breast cancer, and other solid tumors.

Dovitinib is a pan-tyrosine kinase inhibitor targeting fibroblast growth factor receptor (FGFR), vascular endothelial growth factor receptor (VEGFR) and other receptor tyrosine kinases (RTKs). Dovitinib binds to and inhibits the phosphorylation of type III-V RTKs, such as vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) that promote tumor cell proliferation and survival in certain cancer cells. In addition, this agent also inhibits other members of the RTK superfamily, including fibroblast growth factor receptor 1 and 3, FMS-like tyrosine kinase 3, stem cell factor receptor (c-KIT), and colony stimulating factor receptor 1. This may further lead to a reduction of cellular proliferation and angiogenesis, and an induction of tumor cell apoptosis.

TKI258 is a yellow to orange and/or brownish tinged, nonhygroscopic solid that dissociates into TKI258 free base and lactic acid between 125 to 250oC.

Platform Patents
PCT/US2003/010463

Product-Specific Patents
PCT/US2001/042131
PCT/EP2011/055906
PCT/EP2011/060949
PCT/US2013/023781
PCT/US2003/010463
PCT/US2012/029205

Field of Use
Field of use is for the treatment of Cancer.

IPSCIO Record ID: 27879

License Grant
Licensors hereby grant to Licensee an exclusive, worldwide license, including the right to sublicense, under Licensor Patent Rights and Future Patent Rights, to make, have made, use, sell, import and export Products.
License Property
Methods for Therapy Sensitization by Inhibition of Jun Kinase Patent Attorney Docket No. P-UR 2590 (2841302).
Field of Use
The term Field shall mean methods for therapy sensitization by the inhibition of jun kinase and/or the claims specified in the patent application.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.